Below is a summary of treatment options for Crohn's disease (CD).^1-5

Treatment Administration Uses Aminosalicylates Oral Enema Suppository Commonly prescribed for mild to moderate disease Corticosteroids Oral Enema Rectal foam Suppository IV Commonly prescribed for moderate to severe disease; for mild to moderate disease of the ileocecal region (budesonide only) Antibiotics Oral IV Commonly prescribed for mild to moderate disease. Induction of remission in patients with mild to moderate disease; perianal, fistulizing, or refractory disease; postsurgery to prevent flare-ups Immunosuppressants Oral IM and SC (methotrexate only) Commonly prescribed for moderate to severe disease; maintenance of remission; reduction of steroid use Biologic CIMZIA (certolizumab pegol) Subcutaneous injection FDA approved and indicated for reducing signs and symptoms of disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy Biologic HUMIRA® (adalimumab) Subcutaneous injection FDA approved and indicated for reducing signs and symptoms, and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy; reducing signs and symptoms, and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab Biologic Remicade® (infliximab) IV infusion FDA approved and indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult and pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy; reduction of the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure Biologic TYSABRI® (natalizumab) IV infusion FDA approved and indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-alpha

Note: Chart does not imply comparable safety, efficacy, or indications.

NEXT: Safety Information »

Indication
CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.

Important Safety Information
Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies also have been reported in children and adolescents. CIMZIA is not indicated for use in pediatric patients.

*The CIMZIA Co-Pay Savings Card Program is valid for out-of-pocket expenses for CIMZIA for up to 17 uses. The CIMZIA Co-Pay Savings Card Program is not valid for prescriptions that are reimbursed, in whole or part, under Medicare (including Medicare Part D), Medicaid, similar federal or state funded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), private insurance in the Commonwealth of Massachusetts, or where otherwise prohibited by law. Product dispensed pursuant to program rules and federal and state laws. Claims should not be submitted to any public payor (i.e., Medicare, Medicaid, Medigap, Tricare, VA and DoD) for reimbursement. The parties reserve the right to amend or end this program at any time without notice.